| [1] |
GURIA S, HOORY A, DAS S, et al. Adipose tissue macrophages and their role in obesity-associated insulin resistance: an overview of the complex dynamics at play[J]. Biosci Rep, 2023, 43(3): BSR20220200.
|
| [2] |
UGUR K, ERMAN F, TURKOGLU S, et al. Asprosin, visfatin and subfatin as new biomarkers of obesity and metabolic syndrome[J]. Eur Rev Med Pharmacol Sci, 2022, 26(6): 2124-2133.
|
| [3] |
ROMERE C, DUERRSCHMID C, BOURNAT J, et al. Asprosin, a fasting-induced glucogenic protein hormone[J]. Cell, 2016, 165(3): 566-579.
|
| [4] |
COPPOLA I, BROUWERS B, MEULEMANS S, et al. Differential effects of furin deficiency on insulin receptor processing and glucose control in liver and pancreatic β cells of mice[J]. Int J Mol Sci, 2021, 22(12): 6344.
|
| [5] |
FERRERO R, RAINER P, DEPLANCKE B. Toward a consensus view of mammalian adipocyte stem and progenitor cell heterogeneity[J]. Trends Cell Biol, 2020, 30(12): 937-950.
|
| [6] |
LIU X, LU J C, NI X Y, et al. FASN promotes lipid metabolism and progression in colorectal cancer via the SP1/PLA2G4B axis[J]. Cell Death Discov, 2025, 11(1): 122.
|
| [7] |
ZHOU J Q, LIN L, CAI H, et al. SP1 impacts the primordial to primary follicle transition by regulating cholesterol metabolism in granulosa cells[J]. FASEB J, 2023, 37(2): e22767.
|
| [8] |
FENG P, CHE Y, GAO C Y, et al. Profibrotic role of transcription factor SP1 in cross-talk between fibroblasts and M2 macrophages[J]. iScience, 2023, 26(12): 108484.
|
| [9] |
CHEN H, SUN L J, FENG L, et al. Intermittent fasting promotes type 3 innate lymphoid cells secreting IL-22 contributing to the beigeing of white adipose tissue[J]. eLife, 2024, 12: RP91060.
|
| [10] |
ZHANG Y H, ZHU Z M, SUN L J, et al. Hepatic G protein-coupled receptor 180 deficiency ameliorates high fat diet-induced lipid accumulation via the Gi-PKA-SREBP pathway[J]. Nutrients, 2023, 15(8): 1838.
|
| [11] |
ZHU Z M, YANG Y X, SUN L J, et al. GPR180 reduces adiposity by inhibiting lipogenesis and fatty acid uptake in adipocytes[J]. Am J Physiol Endocrinol Metab, 2025, 328(3): E410-E419.
|
| [12] |
LIANG Y, LUO C, SUN L J, et al. Reduction of specific enterocytes from loss of intestinal LGR4 improves lipid metabolism in mice[J]. Nat Commun, 2024, 15(1): 4393.
|
| [13] |
SHI S, WANG J C, GONG H, et al. PGC-1α- coordinated hypothalamic antioxidant defense is linked to SP1-LanCL1 axis during high-fat-diet-induced obesity in male mice[J]. Antioxidants, 2024, 13(2): 252.
|
| [14] |
BROUWERS B, COPPOLA I, VINTS K, et al. Loss of Furin in β-cells induces an mTORC1-ATF4 anabolic pathway that leads to β-cell dysfunction[J]. Diabetes, 2021, 70(2): 492-503.
|
| [15] |
HONG T, LI J Y, WANG Y D, et al. High serum asprosin levels are associated with presence of metabolic syndrome[J]. Int J Endocrinol, 2021, 2021: 6622129.
|
| [16] |
JIANG J F, ZHOU Z Y, LIU Y Z, et al. Role of Sp1 in atherosclerosis[J]. Mol Biol Rep, 2022, 49(10): 9893-9902.
|
| [17] |
WICHAIYO S, KOONYOSYING P, MORALES N P. Functional roles of furin in cardio-cerebrovascular diseases[J]. ACS Pharmacol Transl Sci, 2024, 7(3): 570-585.
|
| [18] |
YOU M, LIU Y S, WANG B W, et al. Asprosin induces vascular endothelial-to-mesenchymal transition in diabetic lower extremity peripheral artery disease[J]. Cardiovasc Diabetol, 2022, 21(1): 25.
|
| [19] |
SUMMERS K M, BUSH S J, DAVIS M R, et al. Fibrillin-1 and asprosin, novel players in metabolic syndrome[J]. Mol Genet Metab, 2023, 138(1): 106979.
|
| [20] |
QUAN C, ZHU S S, WANG R Z, et al. Impaired SERCA2a phosphorylation causes diabetic cardiomyopathy through impinging on cardiac contractility and precursor protein processing[J]. Life Metab, 2022, 1(1): 54-66.
|
| [21] |
MADHOUN AAL, MOHAMMAD A, ABU-FARHA M, et al. FURIN R81C variant: a link to type 2 diabetes via impaired enzymatic activity[J]. Am J Physiol Endocrinol Metab, 2025, 329(1): E179-E189.
|